Breaking News

Recipharm Acquires Italian CDMO

February 24, 2016

Deal adds scale and niche technology in injectable beta lactams

Recipharm has entered into an agreement to acquire Italian contract development and manufacturing organization (CDMO) Mitim for €68 million, adding scale and capabilities to the group. Mitim is currently owned by a private Italian family and is specialized in the filling of injectable beta lactam products. It is located in Brescia close to Recipharm’s existing operations in Northern Italy.

“This acquisition is very exciting for Recipharm and represents an important step in our consolidation of the CDMO industry,” said Thomas Eldered, chief executive officer, Recipharm. “The transaction also cements our leading position in beta lactam production and provides Recipharm not only with additional scale but also opportunities to realize commercial and operational synergies as we combine it with our existing Italian business.”


Mitim’s product portfolio includes beta lactams in dry sterile powder for injectable solutions, tablets and oral suspensions. Other products include injectable sterile solutions, oral solids and liquids as well as semi-solids. The manufacturing site has five production lines and the company completed a significant investment in a new state-of-the-art production line for injectable beta lactams in March 2015. Mitim employs approximately 250 people.

Related Contract Manufacturing:

Related Packaging:

  • Packaging Equipment Technology Preview

    Packaging Equipment Technology Preview

    February 15, 2017
    Today’s complex drug products present challenges; the latest equipment capabilities help overcome them

  • The Good, the Bad, and the Donald

    The Good, the Bad, and the Donald

    January 31, 2017
    Orphan drugs, CMO continuous manufacturing and developing world sales offer biggest revenue opportunities

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks